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This is a case report in which a 60-year-old man who suﬀered from ventricular tachycardia with dilated cardiomyopathy was
prescribed amiodarone. After taking amiodarone, liver enzymes were increased and computed tomographic (CT) scanning of the
abdomen showed a signiﬁcant increase in the density of the liver without contrast medium. He was suspected as hemochromatosis
and liver biopsy was performed. An abnormal high density of liver tissue may be observed in an unenhanced CT in patients treated
with amiodarone and we suggest that periodic monitoring of liver function and/or liver biopsy is warranted before an irreversible
stage is reached.
Copyright © 2009 Sunao Kojima et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Amiodarone is an antiarrhythmic drug used in patients
with refractory supraventricular and ventricular tachycar-
dia and is available worldwide. Pulmonary ﬁbrosis is the
most well-known complication of amiodarone. Abnormal
liver function is also well known, however, that long-term
treatmentwithamiodaroneincreasescomputedtomography
(CT) density of the liver by the iodinated drug/metabolites
h a sn o tb e e nr e p o r t e dr e c e n t l y .I nt h i sp a p e r ,w ed e s c r i b ea n
abnormalhighdensityoflivertissueinanunenhancedCTin
apatienttreatedwithamiodaroneandagreatconsequenceof
periodic monitoring of liver function and/or liver biopsy.
2.CaseReport
A 60-year-old man who suﬀered from ventricular tachy-
cardia with dilated cardiomyopathy was prescribed 400mg
amiodarone daily. About 18 months after taking amio-
darone, liver enzymes were noted to have increased and
computed tomographic (CT) scanning of the abdomen
showed a signiﬁcant increase in the density of the liver
without contrast medium, compared to that of the spleen
and surrounding tissues (113 Hounsﬁeld units (H), normal
range of the liver is about 30–70H, Figure 1). Primary
hemochromatosis was suspected. A liver biopsy was per-
formed under direct laparoscopic visualization. However,
he developed complete atrioventricular block immediately
after the procedure and was transferred to Kumamoto Uni-
versity Hospital for urgent insertion of a temporary pacing
lead. Amiodarone blood concentration was 1554ng/mL and
the level of its active metabolite desethylamiodarone was
1456ng/mL. Hematoxylin and eosin staining of the liver
biopsy revealed mild expansion of the portal area without
intrinsic hepatocellular disease. No evidence of abnormal
hemosiderindepositionwasobservedinBerlinbluestaining.
The striking feature, however, was ﬁne granular depositions
in the macrophages that accumulated in the portal area
(Figure 2(a)). These ﬁne granules showed distinct staining
patternsinvariousstainingmethodsasfollows:periodicacid
Schiﬀ: purple red, Ziehl-Neelsen: dark red, Sudan Black B:
black, Nile blue: blue, Schmorl: light blue (data not shown),
and Leuco malachite green: green (Figure 2(b)). Based on
these staining patterns, the ﬁne granular depositions were
considered to be lipopigments (ceroid and lipofuscin).
Marked ﬁbrosis and bridging necrosis within the portal2 Cardiology Research and Practice
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Figure 1: Abdominal computed tomographic scanning through liver and spleen. Note the marked increase in liver density (113 Hounsﬁeld
units) compared to the spleen.
(a) (b)
Figure 2: Photomicrographs of a liver biopsy. (a) Macrophages inﬁltrate into the portal area and contain achromatic ﬁne granular
depositions (arrows, hematoxylin, and eosin staining). (b) Fine granules are stained green in Leuco malachite green staining (arrows).
Magniﬁcation, ×400.
spaces consistent with liver cirrhosis were not observed. At
about 3 months after withdrawal of amiodarone, the liver
enzymes returned to normal levels and the liver density
became normal (63H, Figure 3). Furthermore, amiodarone
and desethylamiodarone became undetectable in the blood
at about 6 months after cessation of amiodarone.
3. Discussion
Amiodarone and desethylamiodarone are likely to accumu-
late in the liver rather than skeletal muscle and spleen [1].
Furthermore, the levels of amiodarone and desethylamio-
darone correlate with liver CT density [2]. Amiodarone
(2-butyl-3-benzofuranyl 4-[2-(diethylamino) ethoxy]-3, 5-
diiodophenyl ketone hydrochloride) contains two atoms of
iodine, which account for about 37% of the molecular
weight of the drug. The accumulation of amiodarone and
desethylamiodarone leads to increased iodine content within
the liver. Hence, the increased hepatic CT density is probably
due to the high concentration of the iodinated drug and its
metabolite.
The staining pattern of granular depositions is similar to
that of neuronal ceroid lipofuscinosis, which is characterized
by accumulation of lysosomal autoﬂuorescent lipopigments
(ceroid and lipofuscin) resulting in part from the reduced
phospholipase activity [3]. Although the precise mechanism
is not elucidated, amiodarone accumulates in lysosomes of
macrophagesandinteractswithphospholipidstoformdrug-
lipid complexes, which seem to be protected from enzymatic
attackbyphospholipase,leadingtoasecondaryphospholipi-
dosis. This amiodarone-associated phospholipidosis may be
observed as ﬁne granular depositions in the macrophages of
liver biopsy.
Hepatic enzymes and CT density of the liver normalized
after cessation of amiodarone in the present case. Several
clinical reports about abnormal high density of the liverCardiology Research and Practice 3
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Figure 3: Normalization of CT density of the liver after 6-month
discontinuation of amiodarone (63 Hounsﬁeld units).
in patients treated with amiodarone have been published.
However, reports similar to the present case demonstrat-
ing liver biopsy as well as periodic monitoring of liver
function, blood amiodarone levels and CT density of the
liver after cessation of amiodarone are limited. Hepatic
function is in general reversible if amiodarone is withdrawn
in the early phase. However, hepatotoxicity is considered
by amiodarone-induced inhibition of mitochondrial β-
oxidation and subsequent production of reactive oxygen
species. These series may cause apoptosis and necrosis
of hepatocytes, leading to nonalcoholic steatohepatitis [4].
In fact, a previous case report showed that long-term
administration of amiodarone induced liver cirrhosis [5].
Amiodarone is a clinically beneﬁcial drug in refrac-
tory cases of supraventricular and ventricular arrhythmias.
However, an abnormal high density of liver tissue may be
observed in an unenhanced CT in patients treated with
amiodarone and we suggest that periodic monitoring of
liver function and/or liver biopsy is warranted before an
irreversible stage is reached.
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